Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Targeted Therapy Market Size Changed, over the years?

The market size of targeted therapy has significantly increased in the past few years. The market, which was valued at $103.84 billion in 2024, is projected to expand to $111.47 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.3%. Innovations in molecular biology, the rising prevalence of cancer, the personalization of medicine, endorsements from the FDA, and a supportive regulatory environment are all contributing factors to this historic growth period.

How Much Will the Targeted Therapy Market Be Worth in 2029?

The targeted therapy market is projected to experience significant growth in the approaching years. The market is estimated to reach a value of $151.48 billion in 2029, with a compound annual growth rate (CAGR) of 8.0%. This market expansion in the forecast period is due to the growth in oncology research, an increase in demand for precision medicine, the advent of immunotherapies, increased funding in biopharmaceuticals, along with patient enlightenment and advocacy. Key trends for the forecast period include the application of artificial intelligence (AI) in drug innovation, patient advocacy influencing treatment choices, the growth of companion diagnostics, regulatory support favoring rapid approvals, and amplified investment in the biotechnology and pharmaceutical sectors.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9129&type=smp

Which is the Largest Company in the Targeted Therapy Market?

Major companies operating in the targeted therapy market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Genmab A/S, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Agilent Technologies Inc., Illumina Inc., Incyte Corporation, Sysmex Corporation, Exact Sciences Corporation, Seagen Inc., Exelixis Inc., Seattle Genetics Inc., Genentech Inc., Daiichi Sankyo Company Limited

What Are the Main Market Drivers in the Targeted Therapy Industry?

The rising incidence of cancer is anticipated to stimulate the advancement of the targeted therapy market. Cancer refers to conditions in which abnormal cells can multiply uncontrollably and harm surrounding tissues. Targeted therapy has the ability to counteract the signals that catalyze the proliferation of cancer cells or induce self-destruction in cancer cells. The drugs used in this therapeutic strategy specifically aim at genes and proteins facilitating the growth and survival of cancer cells, thereby amplifying its demand. For example, the American Cancer Society, a nonprofit cancer advocacy organization based in the US, reported that the cancer cases escalated to 2,001,140 in January 2024 as compared to 1,958,310 in 2023, marking a surge of 2.19%. As a result, the escalating cancer prevalence will be a pivotal driving force for the targeted therapy market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9129&type=smp

How Is the Targeted Therapy Market Segments Structured?

The targeted therapy market covered in this report is segmented –

1) By Type: Small Molecule Medicines, Monoclonal Antibodies

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Renal Cancer, Other Applications

Subsegments:

1) By Small Molecule Medicines: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors, Other Small Molecule Therapies

2) By Monoclonal Antibodies: Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), Cytokine Blockers, Other Monoclonal Antibodies

What Strategic Trends Are Transforming the Targeted Therapy Market?

Key players within the targeted therapy sector are striving to advance new technological solutions to consolidate their market presence. For instance, a major Switzerland-based multinational pharmaceutical corporation, Novartis AG, introduced Pluvicto in March 2022, having received approval from the US Food and Drug Administration (FDA). This is the first FDA-sanctioned targeted radioligand therapy (RLT) for qualified patients suffering from mCRPC. Pluvicto merges a therapeutic radioisotope with a targeted chemical, also known as a radioactive particle, forming a unique type of targeted cancer therapy. Pluvicto attaches to target cells in the bloodstream, such as prostate cancer cells that express the transmembrane protein PSMA. Upon attachment, the energy emissions from the radioisotope damage these target cells along with nearby cells, thereby preventing replication and/or inducing cell death.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Which Global Regions Offer the Highest Growth in the Targeted Therapy Market?

North America was the largest region in the targeted therapy market in 2024. The regions covered in the targeted therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9129

This Report Delivers Insight On:

1. How big is the targeted therapy market, and how is it changing globally?

2. Who are the major companies in the targeted therapy market, and how are they performing?

3. What are the key opportunities and risks in the targeted therapy market right now?

4. Which products or customer segments are growing the most in the targeted therapy market?

5. What factors are helping or slowing down the growth of the targeted therapy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model